Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 29, 2025
Reporting Period: First six months of 2025 (H1 2025) and Second Quarter 2025.
Context: The company reported H1 2025 financial results and significantly lowered its full-year 2025 sales and operating profit outlook due to slower-than-expected growth in key US markets and competition.
Key Financial Metrics
Performance (Constant Exchange Rates - CER)
- Sales Growth (H1 2025): 18% (Q2 2025: 18%)
- Operating Profit Growth (H1 2025): 29% (Q2 2025: 40%)
- Diluted Earnings Per Share (H1 2025): DKK 12.49 (Q2 2025: DKK 5.96)
Full-Year 2025 Outlook (Updated)
- Sales Growth (CER): 8-14% (Previously 13-21%)
- Operating Profit Growth (CER): 10-16% (Previously 16-24%)
- Free Cash Flow: Expected DKK 35-45 billion
- Financial Items (Net): Expected gain of approx. DKK 3 billion
Note: Sales and operating profit growth in Danish kroner are expected to be 4 and 7 percentage points lower than CER figures, respectively, due to USD/DKK depreciation.
Material Changes vs. Prior Period
- Outlook Reduction: Full-year sales and operating profit guidance was lowered significantly compared to May 7, 2025 expectations.
- Revenue Drivers: H1 2025 sales were positively impacted by gross-to-net adjustments related to prior years, including a DKK 3 billion adjustment for the 340B provision in Q2 2025.
- Profit Drivers: Operating profit growth benefited from the absence of the Ocedurenone impairment recorded in Q2 2024, partially offset by costs related to the acquisition of three Catalent manufacturing sites.
Guidance, Risks, and Management Commentary
Reasons for Lowered Outlook
- US Obesity Market (Wegovy): Slower market expansion, persistent use of compounded GLP-1s, and competition. Despite the FDA grace period for mass compounding expiring on May 22, 2025, unlawful compounding continues.
- US Diabetes Market (Ozempic): Negative impact from competition.
- International Markets: Lower-than-expected penetration for Wegovy in select markets due to slower expansion and competition.
Strategic Initiatives and Risks
- Compounding Litigation: Novo Nordisk is pursuing litigation against entities selling compounded GLP-1s under false pretenses to protect patients from unsafe drugs.
- Direct-to-Patient: Launched NovoCare Pharmacy in March 2025; currently handling ~11,000 weekly prescriptions, alongside ~20,000 in the retail cash channel.
- Regulatory: Awaiting a regulatory decision on the Wegovy MASH indication in H2 2025.
- Formulary Changes: Anticipates positive contribution from CVS national template formulary changes effective July 1, 2025, making Wegovy the only covered GLP-1 for obesity.
Investor Verification Checklist
- Compounding Impact: Verify the extent of continued mass compounding of semaglutide post-May 2025 and the efficacy of ongoing litigation.
- 340B Adjustments: Confirm the sustainability of the DKK 3 billion gross-to-net adjustment in Q2 2025 and its impact on future net sales.
- Catalent Integration: Assess the ongoing financial impact of the three Catalent manufacturing site acquisitions on operating margins.
- Exchange Rate Sensitivity: Monitor USD/DKK fluctuations, as the filing notes a significant divergence between CER and local currency growth expectations.
- Full Disclosure Date: Await the full financial results disclosure scheduled for August 6, 2025, for detailed currency breakdowns and segment data.